Omega-3
Long-chain omega-3 fatty acids (EPA and DHA)
Written by Aaron CuhaReviewed Sep 2026
Also known as: Fish oil, EPA, DHA, Eicosapentaenoic acid, Docosahexaenoic acid, Icosapent ethyl
Two large outcome trials reached opposite conclusions and the difference may be the placebo. Blood levels track strongly with living longer, supplements mostly do not, and the atrial fibrillation risk is real and dose-dependent.
Overview
Omega-3 is the most interesting evidence problem in this pillar because the literature contains a genuine, unresolved dispute rather than a simple null. One trial of 8,179 patients found a large reduction in cardiovascular events. Another trial in a comparable population found nothing. The leading explanation is not the drug, it is what the control group was given.
Separately, the observational data are among the strongest for any nutrient. Pooled across 17 cohorts, people with the highest blood omega-3 levels had roughly 15 to 18% lower mortality. That is a blood level rather than a supplement, which is the distinction this whole pillar keeps returning to, and it is why an omega-3 index test is more useful than a bottle.
One thing is clearer than most people assume: there is a dose-dependent increase in atrial fibrillation. The common belief that fish oil has no downside is wrong.
Mechanism of action
EPA and DHA incorporate into cell membrane phospholipids, displacing arachidonic acid and altering membrane fluidity and the substrate pool for eicosanoid synthesis. They are precursors to resolvins and protectins, which actively terminate inflammation rather than merely failing to promote it. EPA lowers hepatic triglyceride synthesis and secretion, which is the basis of the prescription high-dose indication. DHA is a major structural lipid in retina and brain. The membrane effects also alter cardiac ion channel behaviour, which is the most plausible route to the atrial fibrillation finding.
Human evidence
Very large randomised base, split by dose and formulation. At supplement doses in general populations, the outcome trials are null. At prescription doses in high-risk patients, one trial is strongly positive and one is null.
- REDUCE-IT, 8,179 high-risk statin-treated patients, 4 g icosapent ethyl daily: large reduction in major cardiovascular events against a mineral oil placebo.
- STRENGTH, comparable population, high-dose omega-3 against corn oil: null, stopped for futility.
- VITAL, 25,871 general-population adults, 1 g daily: primary cardiovascular endpoint missed.
- 17 pooled prospective cohorts: highest blood omega-3 quintile carried roughly 15 to 18% lower mortality than the lowest.
- VITAL-RHYTHM: omega-3 was associated with increased incident atrial fibrillation, and the wider randomised literature shows the risk rising with each additional gram per day.
- Mean omega-3 index in Western populations sits well below the 8 to 10% often cited as a target, which is the practical argument for supplementation in someone who does not eat oily fish.
What this does not tell you: The central dispute is unresolved and this page does not resolve it. The mineral oil objection to REDUCE-IT is that the placebo arm showed rises in LDL and inflammatory markers, which would widen the between-arm gap without the drug doing more. The published defence of that placebo appeared in a manufacturer-funded journal supplement with a manufacturer co-author, and the lead author chaired the manufacturer's data monitoring committee. Note also what does not transfer: 4 g of purified prescription EPA is not a fish oil capsule, and a positive result in high-risk patients on statins does not extend to a healthy person.
Reading the research record
This is the best teaching example in supplement evidence, because the disagreement is not between good and bad science. Both REDUCE-IT and STRENGTH were large, randomised, well-conducted outcome trials, and they disagree. The most-discussed explanation is the comparator: mineral oil in one, corn oil in the other. If mineral oil is not inert, the positive trial's effect size is partly a placebo-arm artefact.
That explanation is contested, and the contest is worth disclosing in both directions. The defence of mineral oil has industry fingerprints on it, as described above. The critique also comes partly from people with competing commercial interests. What a reader should take away is not a verdict but a boundary: there is one prescription formulation with one positive outcome trial under dispute, and a general fish oil supplement has no positive outcome trial at all.
The evidence, charted
Fig. 1 · evidence composition
5of 5 citations (100%) are in people
Every citation cited here is Human work; no other study type is cited on this page. This count is of our own citation list and understates any literature larger than the sources we cite.
Fig. 2 · evidence over time
Evidence spans 3 distinct years, 2019 to 2021, counted from the citation list on this page.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four jurisdictions shown. A jurisdiction's classification is a regulatory fact, not a verdict on the science; see Legal status below for the full text and any notes.
Fig. 4 · dose response
No human dose response curve exists
We draw this figure where the data supports it. For this compound in humans it does not, so the panel stays empty rather than borrowing an animal curve and implying it transfers.
Key studies & citations
- Human2019
Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia
REDUCE-IT. 8,179 statin-treated patients with raised triglycerides randomised to 4 g of icosapent ethyl daily or a mineral oil placebo. A large reduction in major cardiovascular events. The positive half of the dispute, and the placebo is the contested part.
New England Journal of Medicine - Human2020
Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk (STRENGTH)
The null half. A high-dose omega-3 against a corn oil placebo in a comparable high-risk statin-treated population produced no reduction in major adverse cardiovascular events. The trial was stopped for futility.
JAMA - Human2021
Blood n-3 fatty acid levels and total and cause-specific mortality from 17 prospective studies
Pooled across 17 prospective cohorts. The highest blood omega-3 quintile carried roughly 15 to 18% lower mortality than the lowest. Observational, and the exposure is a measured blood level rather than a supplement taken.
Nature Communications - Human2021
Effect of marine omega-3 fatty acid and vitamin D supplementation on incident atrial fibrillation
VITAL-RHYTHM, the prespecified atrial fibrillation analysis inside the 25,871-participant VITAL trial. Omega-3 was associated with increased incident atrial fibrillation. Across the wider randomised literature the signal rises with dose.
JAMA - Human2019
Vitamin D supplements and prevention of cancer and cardiovascular disease
VITAL also randomised 1 g a day of marine omega-3 in the same 25,871 participants. That arm missed its primary cardiovascular endpoint too, which is the general-population answer at a supplement-level dose.
New England Journal of Medicine
Frequently asked questions
Does fish oil prevent heart attacks?
At supplement doses in a general population, the largest randomised trials say no. VITAL randomised 1 g a day in 25,871 people and missed its cardiovascular endpoint. The one strongly positive trial used 4 g a day of a prescription purified EPA in high-risk statin-treated patients, and its placebo is disputed.
How do I know how much I need?
Test an omega-3 index, which measures EPA and DHA as a percentage of red cell fatty acids. Most Western adults come in well under the 8 to 10% commonly used as a target. Retest at about 120 days, not at 30, because red cell membranes take that long to reach steady state.
Is there a downside?
Yes, and it is underreported. Omega-3 supplementation is associated with increased atrial fibrillation, and the risk rises with dose. If you already have arrhythmia or are prone to it, that is a specific reason to discuss dose with a clinician rather than escalate on your own.
EPA or DHA, ethyl ester or triglyceride?
The cardiovascular trials that were positive used purified EPA as an ethyl ester. Trials using mixed EPA and DHA have been less consistent. Triglyceride forms absorb somewhat better with a meal. None of these differences has been tested head to head on a clinical outcome, so anyone telling you one form prevents heart disease better than another is ahead of the evidence.